Background {#Sec1}
==========

About one in ten diagnosed with bipolar disorder (BD) has experienced a premorbid traumatic brain injury (TBI) (Sagduyu [@CR42]; Orlovska et al. [@CR35]; Chi et al. [@CR9]). An association between TBI and risk of BD is established by nation-wide cohort studies from Denmark (Orlovska et al. [@CR35]) and Taiwan (Chi et al. [@CR9]) and a meta-analysis of prior smaller studies (Perry et al. [@CR36]). The nature of this association could theoretically include inverse causation, confounding, and causation (Malaspina et al. [@CR30]). A review on the topic using Bradford Hill's criteria finds evidence for a causal relationship in some cases (van Reekum and Cohen [@CR55]). The American Psychiatric Association also acknowledges that TBI can cause BD (American Psychiatric Association [@CR1]).

The Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM 5) distinguishes between a diagnosis of BD and a diagnosis of bipolar and related disorder due to another medical condition (in the context of this paper abbreviated to BD due to TBI) (American Psychiatric Association [@CR1]). To fulfil the criteria of the latter, there must be evidence from the history (e.g. an acute or subacute onset of the mood disturbance after the onset of the general medical condition), physical examination, or laboratory findings that the mood disturbance is the direct physiological consequence of the general medical condition. Similar criteria exist for the corresponding diagnosis in the DSM fourth edition (DSM IV) (American Psychiatric Organization [@CR2]). Thus, among patients with symptoms of BD, a premorbid TBI does not per se qualify for a diagnosis of BD due to TBI.

The validity of this dichotomy between BD *with* premorbid TBI and BD *due to* TBI is questionable (Kendell and Jablensky [@CR24]). First, BD has a non-absolute monozygotic concordance (Craddock and Sklar [@CR12]). Environmental factors must thus be of some etiological importance in both diagnoses. Second, a latency in the onset of BD after TBI does not exclude a pathophysiological impact of the latter. In a nation-wide sibling-controlled cohort study from Sweden (Sariaslan et al. [@CR43]), TBI predicted risks of later psychiatric visits and hospitalizations. The risks were also increased among those with TBI in childhood and of mild severity. Even though these findings were not stratified by diagnoses, they highlight the possibility of a causative effect of TBI in childhood on psychiatric disorders in adulthood. Third, TBI can induce a range of pathophysiological processes which are not necessarily detected by standard radiological or electrophysiological assessment (Mayer et al. [@CR31]; Nuwer et al. [@CR34]; Blennow et al. [@CR6]).

It is thus possible that TBI could have had an impact in the pathophysiological trajectory of BD in some patients who do not fulfil the criteria of BD due to TBI. If so, these patients would be expected to have some of the same clinical characteristics as previously described in BD due to TBI. Such clinical characteristics are more aggression and irritability, and a high hypomania/mania:depression ratio (Shukla et al. [@CR47]; Jorge et al. [@CR23]). Clinical characteristics of BD with premorbid TBI could obviously be influenced by other factors than the TBI. Family history of mental illness is particularly of relevance, since it is associated with both risk of TBI (Malaspina et al. [@CR30]) and more severe clinical characteristics of BD (Antypa and Serretti [@CR3]). Also, some clinical characteristics (e.g. levels of aggression and irritability) could be sensitive to potential differences between those with and without premorbid TBI in regard to BD subtypes (Baek et al. [@CR5]; Serretti and Olgiati [@CR45]), and mood states (Young et al. [@CR58]) and pharmacological treatment (Müller-Oerlinghausen and Lewitzka [@CR33]) at assessment.

The aim of the present study was to identify clinical characteristics in patients with BD and premorbid TBI, using a large sample of patients from psychiatric care. We hypothesized to find more aggression and irritability, a higher hypomania/mania:depression ratio, and other clinical characteristics distinguishing patients with premorbid TBI from those without. Further, we hypothesized that eventual findings would be independent of possible confounders.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The study has a cross-sectional design.

Setting {#Sec4}
-------

Psychiatric health care services in Norway are publicly funded and the hospitals have catchment area responsibilities. From 2003 to 2012 data were collected from 17 psychiatric hospitals and outpatient clinics collaborating in the Bipolar Research And Innovation Network Norway (BRAIN) study (Morken et al. [@CR32]).

Participants {#Sec5}
------------

Patients diagnosed with BD type I, type II, or not otherwise specified (NOS), or cyclothymia were invited to participate. Diagnoses were confirmed by trained clinicians with the Structured Clinical Interview for DSM IV Axis I Disorders (SCID I) (First et al. [@CR16]) or the Mini-International Neuropsychiatric Interview (M.I.N.I.) (Sheehan et al. [@CR46]). The only exclusion criterion was inability to give informed consent. There is no information available on the number of patients who refused to participate. A total of 549 patients were included. The present study consists of the 505 patients who answered the questions about TBI and age at onset of BD.

Data sources {#Sec6}
------------

All patients were assessed with a Norwegian adaptation of the Network Entry Questionnaire (NEQ). NEQ is a semi-structured interview developed by the Bipolar Collaboration Network (Leverich et al. [@CR27]). The Norwegian adaptation of NEQ was used to obtain data on TBI, demographic factors, family history, course of illness, pharmacological treatment, somatic comorbidity, and psychiatric comorbidity in childhood. The Young Mania Rating Scale (YMRS) (Young et al. [@CR58]) and the Inventory of Depressive Symptomatology Clinician Rated 30 (IDS-C~30~) (Rush et al. [@CR41]) were used to obtain data on symptom composition and burden. The SCID I or the M.I.N.I. were used to obtain data on current mood state.

Variables {#Sec7}
---------

The grouping variable was premorbid TBI. Patients were asked if they had had a head injury with loss of consciousness (LOC) and if they had had a head injury without LOC. The questions could be answered *yes (diagnosed)*, *no*, or *don't know*. An answer of *yes (diagnosed)* thus implicated a prior diagnostic evaluation of a general practitioner or hospital doctor. In Norway, head injuries are in general practice defined according to the International Classification of Primary Care (ICPC) (Brage et al. [@CR7]; Lamberts and Wood [@CR25]), and in hospital settings according to the International Classification of Diseases (ICD) 10th revision (World Health Organization [@CR57]). An ICPC diagnosis of head injury (N79--N80) requires loss of consciousness, neurological sequela, or cerebral injury, while an ICD-10 diagnosis of head injury implies that the criteria for hospital admission (i.e. loss of consciousness, amnesia, reduced responsiveness, focal neurological deficits, or Glasgow Coma Scale Score \< 15) in Norway have been met (Lamberts and Wood [@CR25]; Ingebrigtsen et al. [@CR21]). If answering *yes (diagnosed)*, patients where further asked about their age at the time of diagnosis. We defined premorbid TBI as having received a diagnosis of head injury of any severity at an age lower than age at onset of BD. The definition of age at onset of BD was age at first depressive symptoms associated with dysfunction or first hypomanic or manic symptoms similar to those experienced in adulthood (Morken et al. [@CR32]).

Years of education refers to the accumulated time spent at upper secondary schools, university colleges, and universities.

From variables of family history of mental illness, we computed answers of *yes (diagnosed)* as positive and *probable* or *no* as negative to questions of schizophrenia, BD, and depression in 1st degree relatives.

Duration of illness was calculated as the difference between age at inclusion and age at onset. Variables on affective episodes per year were calculated as fractions of number of episodes above duration of illness. Rapid cycling was dichotomized from a question of four or more episodes per year during lifetime, where answers of *yes* were defined as positive and *no* or *uncertain* were defined as negative. The variable on serious suicidal attempts was defined by lifetime history of suicidal attempts leading to medical assistance, emergency room visit, or hospitalization.

Variables on pharmacological treatment were defined by current use of lithium, anticonvulsants, antipsychotics, and antidepressants.

History of epileptic seizures and comorbid migraine were defined by answers of *yes (diagnosed)* to questions of lifetime history of the two, while answers of *no* or *don't know* were regarded as negative. Obesity was defined as body mass index ≥ 30 kg/m^2^ as calculated from self-reported height and weight. Psychiatric comorbidity was defined by one variable on abuse or dependence of alcohol and a similar variable on other substances, both defined by SCID-I or M.I.N.I., as well as one variable on self-reported diagnosis of childhood attention deficit (hyperactivity) disorder (AD(H)D) obtained from the NEQ.

Variables on symptom composition and burden were obtained from principal components and total scores, respectively, of YMRS and IDS-C~30~ at inclusion (see statistical methods).

Bias {#Sec8}
----

As an indirect test of bias in self-reported variables, we compared the groups on a four-point ordinal item in the NEQ on the clinicians' judgement of the reliability of the patients' answers. The item scores ranged from 1 to 4, corresponding to very reliable and unreliable answers, respectively.

Statistical methods {#Sec9}
-------------------

R (version 3.4.0) ([@CR38]) and RStudio (version 1.0.143) ([@CR39]) were used for statistical analyses.

The R package psych was used for principal component analyses (PCA) of items in the YMRS and IDS-C~30~. The purpose of conducting a PCA was to limit the number of comparisons in analyses of symptomatology. Items on appetite and weight in the IDS-C~30~ are pair-wise optional and were excluded to avoid large amounts of missing data. Cronbach's alpha was used to test the internal reliability of the rating scales. A Kaiser-Meyer-Olkin (KMO) test was used to measure sample size adequacy. A determinant cut-off at \> 0.00001 was used to avoid multicollinearity. The Velicer's map criterion was used to determine the number of components to retain. Direct oblimin oblique rotation was used since components were assumed to be correlated. Pattern matrices of component loadings \> 0.4 were used to interpret the results. Standardized component scores were saved for each participant.

Bivariate analyses of differences between the groups were undertaken for all variables. Pearson's Chi squared tests, Fisher's exact tests, Mann--Whitney U-tests, and independent samples t-tests were used as appropriate. The alpha level was set to \< 0.05. A Bonferroni correction of 40 comparisons, two of which were not included in the paper due to large amounts of missing data, yielded a p-value threshold of \< 0.0013. The beta level for each comparison was not calculated.

A backward likelihood ratio logistic regression analysis was conducted in order to find clinical characteristics associated with premorbid TBI independent of each other and possible confounders. We included variables with p-values \< 0.1 from bivariate analyses, and possible confounding variables based on the literature and clinical experience. These were age, sex, years of education, 1st degree family members with schizophrenia, BD, or depression, rapid cycling, migraine, AD(H)D in childhood, comorbid alcohol abuse or dependence, comorbid substance abuse or dependence, YMRS total score, IDS-C~30~ total score, YMRS disruptive component score, and IDS-C~30~ activated component score. Depressive episodes per year and hypomanic episodes per year were not included due to large amounts of missing data. YMRS total score had a skewed distribution with large amounts of null scores. Logarithmic transformation of total score plus one was therefore used in the regression model.

Further, we built additional logistic regression models to test whether our findings from the backward likelihood ratio logistic regression analysis were dependent on BD subtypes, mood states, and pharmacological treatments. First, we built a base model (Model 1) including sociodemographic factors (age, gender, and years of education), family history of mental illness (schizophrenia, BD, and depression), and clinical characteristics significantly associated with premorbid TBI in the backward likelihood ratio logistic regression analysis (YMRS disruptive component score and comorbid migraine) as independent variables. Then, we added and removed dummy variables of BD subtypes (Model 2a: type 1 vs. others; Model 2b: type 2 vs. others), mood states (Model 3a: depressed vs. others; Model 3b: euthymic vs. others etc.), and pharmacological treatments (Model 4a: lithium vs. others; Model 4b: anticonvulsants vs. others etc.) in successive models.

Variance inflation factors (VIF) between all independent variables were calculated to assess for multicollinearity.

Results {#Sec10}
=======

Sample characteristics {#Sec11}
----------------------

Five hundred five patients were included. Mean age was 42 years (SD 14), 286 (57%) were women, and 256 (53%) had BD type I. Thirty-seven patients (7.3%) reported a premorbid TBI, of whom 23 (4.6%) had LOC. Age at TBI and years from age at TBI to age at onset of BD had mean values of 10 years (SD 9.0) and 8.9 years (SD 7.3), respectively.

Clinicians judged the reliability of the patients' answers as high in both groups (median 1 vs. 1 (interquartile range 1 vs. 1), p = 0.45).

Principal component analyses {#Sec12}
----------------------------

Cronbach's alpha was 0.90 for both YMRS and IDS-C~30~, which implicates a very good internal reliability of the rating scales.

Two components were extracted from items in both YMRS (Table [1](#Tab1){ref-type="table"}) and IDS-C~30~ (Table [2](#Tab2){ref-type="table"}). The KMO measure of sampling adequacy was 0.89 and 0.93, respectively. Barlett's test of spherity was significant for both. The determinant was 0.0017 and 0.000029, respectively. The components accounted for 62% of the variance in the YMRS and 39% of the variance in the IDS-C~30~.Table 1Items loadings on principal components of the Young Mania Rating ScaleItemComponents (variance explained)Elated (37%)Disruptive\
(24%)Elevated mood0.95Increased motor activity/energy0.93Speech0.84Language/thought disorder0.75Sexual interest0.70Content0.56Disruptive/aggressive behavior0.89Irritability0.76Appearance0.69Insight0.65 Table 2Item loadings on principal components of the Inventory of Depressive Symptomatology Clinican Rated 30ItemComponents (variance explained)Depressed\
(31%)Activated\
(9%)Energy/fatiguability0.86Pleasure/enjoyment0.86Involvement0.85Mood (sad)0.78Outlook (future)0.78Reactivity of mood0.74Psychomotor slowing0.68Sexual interest0.67Outlook (self)0.64Suicidal ideation0.64Mood (anxious)0.64Leaden paralysis/physical energy0.63Concentration/decision making0.53Mood variation0.41Psychomotor agitation0.60Mid-nocturnal insomnia0.60Early morning insomnia0.60Sleep onset insomnia0.53Mood (irritable)0.41

Bivariate analyses {#Sec13}
------------------

By applying bivariate analyses with correction for multiple testing, we found more comorbid migraine (36 vs. 13%, p = 0.00030) among patients with premorbid TBI (Table [3](#Tab3){ref-type="table"}).Table 3Demographics, family history, and clinical characteristics in patients with and without premorbid traumatic brain injuryAll (n = 505)+pTBI (n = 37)−pTBI (n = 468)p-valueDemographics Age50541 (15)42 (13)0.74^a^ Female sex50521/37 (57)265/468 (57)1.0^c^ Years of education4954.8 (3.1)4.4 (3.1)0.55^b^Family history Schizophrenia4964/37 (11)9/459 (2.0)0.012^d^ Bipolar disorder4975/37 (14)105/460 (23)0.27^c^ Depression49726/37 (70)199/460 (43)0.0027^c^ Any49727/37 (73)247/460 (54)0.036^c^Mood state Depressed50428/37 (76)305/467 (65)0.27^c^ Euthymic5041/37 (2.7)12/467 (2.6)1.0^c^ Mixed5041/37 (2.7)22/467 (4.7)0.88^c^ Hypomanic5040/37 (0)10/467 (2.1)0.77^c^ Manic5047/37 (19)118/467 (25)0.51^c^Course of illness Age at onset50520 (12)19 (11)0.81^b^ Duration of illness50521 (14)23 (14)0.45^b^ Bipolar disorder subtype5050.57^d^  Type I18/37 (49)247/468 (53)  Type II18/37 (49)213/468 (46)  Cyclothymia0/37 (0)1/468 (2)  Not otherwise specified1/37 (3)7/468 (1) Depressive episodes per year4201.3 (1.8)0.78 (1.1)0.014^b^ Hypomanic episodes per year4241.4 (2.0)0.92 (2.2)0.025^b^ Manic episodes per year4610.073 (0.15)0.091 (0.21)0.23^b^ Hypomania/mania:depression ratio4051.3 (1.1)2.1 (5.2)0.59^b^ Admissions per decade4490.82 (1.1)1.4 (2.6)0.24^b^ Rapid cycling49114/35 (40)103/456 (23)0.034^c^ Serious suicidal attempt(s)50014/37 (38)202/463 (44)0.61^c^Current pharmacological treatment Lithium48312/33 (36)102/450 (23)0.11^c^ Anticonvulsants48320/33 (61)302/450 (67)0.57^c^ Antipsychotics48319/33 (58)270/450 (60)0.93^c^ Antidepressants48312/33 (36)165/450 (37)1.0^c^Comorbidity Epileptic seizures5051/37 (2.7)9/468 (1.9)0.54^d^ Migraine50113/36 (36)59/465 (13)0.00030^c^\* Obesity4984/36 (11)79/462 (17)0.49^c^ Alcohol, abuse or dependence5055/37 (14)64/468 (14)1.0^c^ Other substances, abuse or dependence5052/37 (5.4)28/468 (6.0)1.0^d^ Childhood AD(H)D4976/37 (16)33/460 (7.2)0.059^c^Symptom composition YMRS elated component score4840.12 (1.2)− 0.020 (0.98)0.77^b^ YMRS disruptive component score4840.54 (1.7)− 0.050 (0.90)0.0044^b^ IDS-C~30~ depressed component score4460.19 (1.0)0.011 (1.0)0.30^b^ IDS-C~30~ activated component score4460.21 (0.86)− 0.046 (0.99)0.041^b^Symptom burden YMRS total score4977.9 (11)5.4 (7.8)0.16^b^ IDS-C~30~ total score49028 (14)24 (15)0.087^b^Results are presented by fraction (%) for categorical variables and mean (SD) for continuous variables. +pTBI premorbid traumatic brain injury. −pTBI no premorbid traumatic brain injury\* Multiple comparisons p-value threshold = 0.0013^a^Independent samples t-test^b^Mann--Whitney-U test^c^Pearson's Chi squared test^d^Fisher's exact test

Logistic regression analyses {#Sec14}
----------------------------

Data for 395 of 505 participants (78%) were complete and thereby included in the backward likelihood ratio logistic regression analysis. Among clinical characteristics, the YMRS disruptive component score (OR 1.7, 95% CI 1.1--2.4, p = 0.0077) and comorbid migraine (OR 4.6, 95% CI 1.9--11, p = 0.00090) were independently associated with premorbid TBI (Table [4](#Tab4){ref-type="table"}). Family history of schizophrenia (OR 11, 95% CI 2.3--51, p = 0.0025) was also independently associated with premorbid TBI.Table 4Final step of the backward likelihood ratio logistic regression analysis on variables independently associated with premorbid traumatic brain injury among patients with bipolar disorderCoefficientS.E.OR95% CIWald Zp-valueIntercept− 1.20.360.290.14--0.60− 3.40.00078Family history schizophrenia2.40.79112.3--513.00.0025Comorbid migraine1.50.464.61.9--113.30.00090YMRS disruptive component0.510.191.71.1--2.42.70.0077*S.E.* standard error, *OR* odds ratio, *CI* confidence interval

The associations between premorbid TBI and YMRS disruptive component score and comorbid migraine remained significant after correction for BD subtypes, mood states, and pharmacological treatments (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Nagelkerke R^2^ of 0.31 implied a low relationship between prediction and grouping in the backward likelihood ratio logistic regression analysis. VIF was \< 3.0 between all independent variables in all logistic regression models.

Discussion {#Sec15}
==========

We found that premorbid TBI was associated with comorbid migraine in bivariate analyses with correction for multiple comparisons. In a logistic regression model, we found that premorbid TBI was associated with disruptive symptoms and comorbid migraine independently of a range of possible confounders. Family history of schizophrenia was also independently associated with premorbid TBI. We did not find associations between premorbid TBI and any other clinical characteristics and specifically not with hypomania/mania:depression ratio.

The finding of more disruptive symptoms corresponds with our hypothesis of finding similar clinical characteristics in BD with premorbid TBI as previously described in BD due to TBI (Shukla et al. [@CR47]; Jorge et al. [@CR23]). Aggression and irritability, which in our study had the highest loadings on the disruptive component, are common symptoms after TBI of all severities (Lique Sté Fan and Mathé [@CR28]; Hammond et al. [@CR18]). A cross-sectional study on 89 patients with and without aggression after TBI of all severities, found that aggression was associated with premorbid substance use disorders, affective disorders, and poor social functioning (Tateno et al. [@CR54]). Similarly, a study on 97 children with severe TBI found that preinjury affective lability and psychosocial adversity predicted affective lability (including irritability and temper outbursts) at one year follow-up (Vasa et al. [@CR56]). These studies suggest that TBI could result in more disruptive symptoms among patients with a disposition to affective symptoms and lower social function/support. Further, aggression after TBI was in the same studies associated with frontal lobe lesions (Tateno et al. [@CR54]; Vasa et al. [@CR56]), highlighting a possible structural substrate for disruptive symptoms after TBI. Frontal lobe regions are also implicated in mania secondary to focal brain lesions in general (Satzer and Bond [@CR44]), and are on average thinner among patients with BD than among healthy controls (Hibar et al. [@CR20]).

The mean YMRS score in the premorbid TBI group in our study was low. Further, the association between the YMRS disruptive component score and premorbid TBI remained significant after corrections for BD subtypes, mood states, and pharmacological treatments (Additional file [1](#MOESM1){ref-type="media"}: Table S1). It is thus a possibility that the disruptive symptoms in most patients represent a personality trait related to premorbid TBI rather than a mood state related to BD. However; disruptive symptoms after TBI could also be rapidly alternating (Arciniegas and Wortzel [@CR4]) and thereby resemble, and possibly fulfil the criteria of, short lasting manic states (Coetzer [@CR10]).

Our results are in line with previous findings that migraine is a common headache after TBI (Lucas et al. [@CR29]; Stacey et al. [@CR50]). Inflammation and impaired pain modulation after TBI are two of the suggested pathophysiological mechanisms (Ruff et al. [@CR40]). Furthermore, migraine and BD are bi-directionally associated (Fornaro et al. [@CR17]) and possibly influenced by shared environmental and genetic factors (Sucksdorff et al. [@CR53]). It is thus difficult to conclude on the nature behind our finding of an association between migraine and premorbid TBI among patients with BD.

Although it was not a primary outcome of our study, our finding of more family history of schizophrenia among those with premorbid TBI harmonizes with findings in a study of Malaspina et al. (Malaspina et al. [@CR30]). They assessed for TBI in members of families where at least two 1st degree-relatives had schizophrenia or BD. Members of the schizophrenia pedigrees had an increased risk of TBI which was independent of their own diagnoses. The effect of family history of schizophrenia on risk of premorbid TBI could be mediated by several factors. Examples are co-inherited motor coordination problems (Ismail et al. [@CR22]; Burton et al. [@CR8]), and co-inherited susceptibility to risk-taking behaviour (Strawbridge et al. [@CR52]).

Regarding course of illness, the findings of more rapid cycling, depressive episodes per year and hypomanic episodes per year were not significant after correction for multiple testing. Due to missing data in the latter two variables, only rapid cycling was included in the regression model, and it was not independently associated with premorbid TBI. In the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study, mild TBI after age at onset of BD, but not before, was associated with rapid cycling (Sagduyu [@CR42]). One of several possible explanations to our and the STEP-BD study's findings is that the co-occurrence of TBI and more rapid cycling are epiphenomena of increased genetic susceptibility to BD (Antypa and Serretti [@CR3]). We found a hypomania/mania:depression ratio of 1:1 in the premorbid TBI group, which was not higher than among those without premorbid TBI. In comparison, Shukla et al. reported a ratio of 15:1 in a study on patients with BD due to TBI (Shukla et al. [@CR47]). Several differences between the samples, e.g. regarding clinical setting, severity of TBI, and frequency of comorbid epilepsy, make it difficult to conclude on the cause(s) of this discrepancy.

There were no differences between the groups on current treatment with lithium, anticonvulsants, antipsychotics or antidepressants. Previous studies have found increased treatment response to valproate among patients with BD and a history of TBI (Pope et al. [@CR37]; Stoll et al. [@CR51]). However, treatment response is not directly comparable to our measures, which could be influenced by the prescribing clinicians' preferences and discontinuation due to side effects.

Epilepsy is previously suggested as the pathophysiological mechanism in BD due to TBI (van Reekum and Cohen [@CR55]). In our study of BD with premorbid TBI, self-report did not unveil higher frequencies of epileptic seizures. Nevertheless, not all seizures are recognized by patients (Elger and Hoppe [@CR15]).

The prevalence of premorbid TBI in our study from Norway (7.3%) was lower than in the STEP-BD study from the United States (10% with premorbid mild TBI) (Sagduyu [@CR42]) and in register-based studies from Denmark (11%) (Orlovska et al. [@CR35]) and Taiwan (25%) (Chi et al. [@CR9]). However, both variation in prevalence of TBI across nations and different methodologies across studies (Corrigan et al. [@CR11]) warrant caution when interpreting these differences.

Our study has several limitations that should be taken into account. The reliability and validity of the definition of TBI in the NEQ is unknown. While the definition implies an ICPC or ICD-10 diagnosis of head injury, the NEQ did not harvest data on specific symptoms of head injury or on diagnostic codes from the patients' health records. Self-reported data implies risk of recall bias. It is possible that patients with disruptive symptoms and comorbid migraine look for explanations in the past and thus report a higher prevalence of premorbid TBI. The inter-rater reliability of the diagnostic evaluations was not measured. There exists no data on the overall participation rate. The generalizability of our findings to all patients in psychiatric care is thus unknown. We included patients with all BD subtypes, mood states, and pharmacological treatments. It is possible that our results would have been different if the sample had been restricted to more selected groups, e.g. patients with medication naïve first manic episodes. The Bonferroni correction for multiple testing in the bivariate analyses implies a high risk of type II errors. However, interpretation of the results should be based not only on the Bonferroni corrected p-values alone, but also on the strength of effects, prior knowledge, and biological plausibility of the associations. The design of our study makes it impossible draw conclusions about whether the findings of more disruptive symptoms and comorbid migraine are causal. Inverse causation is an alternative explanation. In regard the association between premorbid TBI and disruptive symptoms, a review found that aggression and irritability are common parts of the distal prodrome of BD (Skjelstad et al. [@CR48]). Aggression and irritability might even characterize a prodromal subgroup of BD type II with neurocognitive deficits (Skjelstad et al. [@CR49]), which can be hypothesized to be more prone to injuries including TBI. Residual confounding could also explain the associations. In our study, disruptive symptoms, comorbid migraine, and family history of schizophrenia were independently associated with premorbid TBI. Taken together, these variables represent a pattern of symptomatology (Hanwella and de Silva [@CR19]), comorbidity (Fornaro et al. [@CR17]), and heritability (Cross-Disorder Group of the Psychiatric Genomics Consortium [@CR13]) typical for BD. We emphasize the possibility that their apparently independent associations with premorbid TBI could be a consequence of residual confounding by genetic susceptibility to BD. Examples of other factors that could have contributed to residual confounding are AD(H)D, which was probably seldom evaluated when the majority of patients in our study grew up, and psychological trauma, on which we have no data despite its known association with more severe clinical characteristics (Leverich and Post [@CR26]) and possibly also with physical trauma including TBI.

Conclusions {#Sec16}
===========

Premorbid TBI is associated with disruptive symptoms and comorbid migraine independently of the measured possible confounders including family history of mental disorders, while it is not associated with an increased hypomania/mania:depression ratio. The finding of more disruptive symptoms is in line with our hypothesis of finding similar clinical characteristics in BD with premorbid TBI as in BD due to TBI. Studies designed to draw conclusions of causal inference from observational data, e.g. by using family-based quasi-experimental designs (D'Onofrio et al. [@CR14]), are warranted to clarify whether our findings could be explained by a continuum of pathophysiological effects of premorbid TBI across the diagnostic dichotomy of BD with premorbid TBI and BD due to TBI.

Additional file
===============

 {#Sec17}

**Additional file 1: Table S1.** Logistic regression models on the associations between premorbid traumatic brain injury and different covariates that could attenuate its associations with the YMRS disruptive component score and comorbid migraine (values given in odds ratios with 95% confidence intervals).

BD

:   bipolar disorder

BRAIN

:   Bipolar Research And Innovation Network Norway

DSM

:   Diagnostic and Statistical Manual of Mental Disorders

ICD

:   International Classification of Diseases

ICPC

:   International Classification of Primary Care

IDS-C30

:   Inventory of Depressive Symptoms Clinician Rated 30

KMO

:   Kaiser-Meyer-Olkin

LOC

:   loss of consciousness

MINI

:   Mini-International Neuropsychiatric Interview

NEQ

:   Network Entry Questionnaire

NOS

:   not otherwise specified

PCA

:   principal component analysis

SCID I

:   Structured Clinical Interview for DSM IV Axis I Disorders

STEP-BD

:   Systematic Treatment Enhancement Program for Bipolar Disorder

TBI

:   traumatic brain injury

VIF

:   variance inflation factor

YMRS

:   Young Mania Rating Scale

UFM, OAA, GM, and AEV designed the BRAIN study. OKD, AEV, and PIF wrote the protocol for the present study. All authors included patients to the BRAIN study. OKD and PIF conducted the analyses. All authors interpreted the results. OKD drafted the manuscript under supervision of AEV and PIF. All authors contributed with the further writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

We want to thank the patients for participating in the study, colleagues for recruitment and interviews, and Thomas D. Bjella for preparation of data.

Competing interests {#FPar2}
===================

UFM has received honoraria from Takeda and Lundbeck for lectures about mood disorders to primary care physicians and psychiatrists. He has also received honoraria from Takeda and Lundbeck Norway for giving scientific advice. OAA has received speaker's honoraria from GSK and Lundbeck. OKD, AEV, GM and PIF report no competing interests.

Availability of data and materials {#FPar3}
==================================

The informed consents do not allow sharing of data to others than collaborating researchers.

Consent for publication {#FPar4}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar5}
==========================================

The Regional Committee for Research Ethics, Central Norway, approved the BRAIN study (ref. 233-04). The study is conducted in accordance with the Helsinki Declaration of 1975. The BRAIN study is registered in ClinicalTrials.gov (ref. NCT00201526, retrospectively registered September 2005). All participants gave written, informed consent.

Funding {#FPar6}
=======

The study was supported by the South-East Norway Health Authority, the KG Jebsen Foundation, and the Research Council of Norway. The funding bodies have not been involved in the design of the present study, in the collection, analysis, or interpretation of data, or in the writing of the manuscript.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
